MYGN
Myriad Genetics, Inc.

2,130
Mkt Cap
$431.07M
Volume
605,623.00
52W High
$11.44
52W Low
$3.76
PE Ratio
-1.17
MYGN Fundamentals
Price
$5.13
Prev Close
$5.01
Open
$4.87
50D MA
$5.69
Beta
1.19
Avg. Volume
918,218.65
EPS (Annual)
-$3.95
P/B
1.17
Rev/Employee
$305,370.37
$629.69
Loading...
Loading...
News
all
press releases
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) have earned a consensus rating of "Hold" from the thirteen brokerages that are currently covering the company, Marketbeat.com reports...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
S. Louise Phanstiel Buys 48,000 Shares of Myriad Genetics (NASDAQ:MYGN) Stock
Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director S. Louise Phanstiel bought 48,000 shares of the company's stock in a transaction dated Friday, February 27th. The shares were purchased...
MarketBeat·3d ago
News Placeholder
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Zacks Research
Zacks Research raised Myriad Genetics from a "strong sell" rating to a "hold" rating in a research report on Thursday...
MarketBeat·3d ago
News Placeholder
Insider Buying: Myriad Genetics (NASDAQ:MYGN) Director Acquires 6,100 Shares of Stock
Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director S. Louise Phanstiel acquired 6,100 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The shares...
MarketBeat·4d ago
News Placeholder
Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel Buys 48,000 Shares
Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director S. Louise Phanstiel purchased 48,000 shares of the business's stock in a transaction dated Friday, February 27th. The shares were...
MarketBeat·4d ago
News Placeholder
S. Louise Phanstiel Acquires 50,407 Shares of Myriad Genetics (NASDAQ:MYGN) Stock
Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director S. Louise Phanstiel purchased 50,407 shares of the firm's stock in a transaction on Thursday, February 26th. The stock was acquired at...
MarketBeat·4d ago
News Placeholder
Wells Fargo & Company Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00
Wells Fargo & Company decreased their price objective on Myriad Genetics from $6.50 to $6.00 and set an "equal weight" rating for the company in a report on Tuesday...
MarketBeat·7d ago
News Placeholder
MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down
Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.
Zacks·7d ago
News Placeholder
Here's What Key Metrics Tell Us About Myriad (MYGN) Q4 Earnings
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·8d ago
News Placeholder
Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates
Myriad (MYGN) delivered earnings and revenue surprises of +350.00% and +1.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
<
1
2
...
>

Latest MYGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.